TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
about
Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicologyDifferential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in ratsnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersEffects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsChronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia.Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorContribution of NMDA receptor hypofunction in prefrontal and cortical excitatory neurons to schizophrenia-like phenotypes.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaThe Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.Alexa Fluor 546-ArIB[V11L;V16A] is a potent ligand for selectively labeling alpha 7 nicotinic acetylcholine receptorsDesign, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Δ2-isoxazoline derivatives as potent and selective agonists of α7 nicotinic acetylcholine receptors.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats.Lynx1 shifts α4β2 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.Pharmacological enhancement of memory and executive functioning in laboratory animals.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophreniaPhase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaA randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT₁a receptor antagonist.Nicotinic receptors in neurodegeneration.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerSpontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Leading compounds for the validation of animal models of psychopathology.Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Understanding the Bases of Function and Modulation of α7 Nicotinic Receptors: Implications for Drug Discovery.Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's DiseaseEffects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds.A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
P2860
Q24627240-69A04C10-69CF-4553-B938-E8C5FB6BB992Q28477881-FF70E1E4-CA4F-4640-9617-94C40E37FB56Q30362464-2C2C2C75-8CD7-4CED-B3A4-4E96D433E6FFQ30372351-AAEC6177-11D0-4317-9A2E-857B81B826DDQ30391389-FE846E5D-9767-43E3-812C-E7576CB30C11Q30415168-8A357488-1741-4281-ACDC-EB794EA4F53DQ30428422-74572FE4-A1EC-4181-9324-4A1844A241CBQ30453198-03345210-4A5E-43E7-B3D4-642A5BC761F6Q30455334-1D108B6C-3D29-4455-91DB-08775F719B68Q30459624-09AEF137-71E5-4CC2-9C0C-38D75D6AD189Q30486732-C339A80E-F617-422B-A1E5-5D6D10DBCF0BQ34004330-D11F3056-59E0-4C8C-ADFE-1C53C49268C8Q34113842-23D5FB67-2B6F-4DDB-BFC6-06D38F7FF258Q34167942-23106D1D-11B1-45DB-B58C-EFBCEDF32743Q34274859-0401B1A7-12AB-4ED8-8A50-A89344BF018DQ34287941-AF342256-B42C-4128-8A2F-295B6021B4B4Q34467639-8982F377-4874-4D89-A9FC-A5938FCCEEEAQ34501147-85E34045-0E5A-4C93-A510-8E3D21F42D2AQ34661221-B4799A96-01C9-45B8-9005-DF07477D59D7Q35048154-B6BA6988-5EE3-4E37-B2E3-B41629F942DBQ35111465-7439B350-AA28-4703-854B-9D20D8788A44Q36088364-0AC7101B-08E0-4309-A71A-F992559A08A2Q36174107-3B12983F-939D-477F-94C8-F899AD75FF9FQ36579938-4ACB65FE-ABF4-42E8-9473-66C55C5A634EQ36775219-31E1227A-168E-4195-AEDC-EE29808159EEQ36807622-337B8094-16A1-42AC-86BF-D7C58CFE2B3BQ36828916-52433B71-0210-4D69-8AC7-169736E8F167Q37258840-27B8C204-B0D2-48C3-8D25-C506C63435CBQ37954123-84B4E2E4-7BC3-434F-8191-ED9958BCABC5Q38022265-0DAE0D69-C8F3-448F-B7CA-4D36202D6325Q38128733-6651AFA6-C620-46DD-9A98-43792624FC41Q38172958-7A342E10-9ACF-4D93-BBBA-5237F3A24FF2Q38286246-95EB0479-DA76-4458-9EDA-6E894B081357Q38560778-720E7DC3-69E7-4DA6-9B9D-86A766C1F418Q38837028-73276D3D-86D6-4198-9B55-0E0F0443360AQ39041214-1B2946BE-32EC-4A3E-A00A-4651E797E4D1Q41449158-1BA8159E-6BA0-4AFC-ACB2-002D953865CAQ42004188-2B25811C-E8D3-48D4-ADB2-3DB018F0E21EQ45961748-E93A4ACD-88F6-4B2A-B47E-D93F1E4F2E09Q46490757-74D931A2-3020-45EA-A142-156BAE40B12D
P2860
TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@ast
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@en
type
label
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@ast
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@en
prefLabel
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@ast
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@en
P2093
P2860
P1476
TC-5619: an alpha7 neuronal ni ...... dysfunction of schizophrenia.
@en
P2093
A Kucinski
E K Stachowiak
K G Jordan
M Bencherif
M K Stachowiak
P M Lippiello
S R Wersinger
P2860
P304
P356
10.1016/J.BCP.2009.05.030
P407
P577
2009-05-29T00:00:00Z